US 2025/0367191 A1Published application

Treatment of mitochondrial diseases with a cns-penetrant sgc stimulator zagociguat

AssigneeTisento Therapeutics Inc.

InventorsChad Edward Glasser, Christopher John Winrow

Life of this patent

Estimating the term…

Abstract

The present invention relates to a method of treating a mitochondrial disease in a patient in need thereof by administering Compound (I), a stimulator of soluble guanylate cyclase (sGC) at certain dosages either alone or in combination therapy.

Claims44

Dependent claims

A method of treating mitochondrial disease in a patient in need thereof comprising administering to said patient a total oral daily dose of between 15 mg and 60 mg of Compound I:

Dependencies are inferred from the claim text.

Facts

Application: 18/872,750Filed 9 Jun 2023
Priority: 9 Jun 2022
Published: 4 Dec 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 31/198
The amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine,…:…
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 25/00
Drugs for disorders of the nervous system

Family

Application63/350,708Us provisional application · filed 9 Jun 2022
Application63/410,829Us provisional application · filed 28 Sep 2022
US 2025/0367191 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results